The DOI matches its Crossref record; 91 of the 91 references it cites were found in a registry or an index.
Pathology of triple negative breast cancer
Abstract
Triple negative breast cancer (TNBC) is a subtype of breast tumor lacking hormone receptors expression and HER2 gene amplification and represents 24% of newly diagnosed breast neoplasms. In this review, pathological aspects of triple-negative breast cancer are illustrated, with particular attention to the seminal studies that defined this subtype of breast cancer by a molecular point of view. This paper also focuses on practical issues raised in clinical routine by the introduction of genetic expression breast cancer profiling and the innovative prognostic and predictive impact on triple-negative breast cancer pathology. Moreover, histopathological aspects of triple-negative neoplasms are also mentioned, underlying the importance of histologic diagnosis of particular cancer subtypes with decisive impact on clinical outcome. Importantly, focus on new therapeutic frontier represented by immunotherapy is illustrated, with particular mention of immune checkpoint inhibitors introduction in TNBC therapy and their impact on future treatments.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Molecular portraits of human breast tumours
Perou, C. M., Sørlie, T., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., Rees, C. A., Pollack, J. R., Ross, D. T., Johnsen, H., Akslen, L. A., et al. (2000) · Nature · doi:10.1038/35021093 · Cited by 16,261
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Lehmann, B. D., Bauer, J. A., Chen, X., Sanders, M. E., Chakravarthy, A. B., Shyr, Y., & Pietenpol, J. A. (2011) · Journal of Clinical Investigation · doi:10.1172/jci45014 · Cited by 5,592
Supervised Risk Predictor of Breast Cancer Based on Intrinsic Subtypes
Parker, J. S., Mullins, M., Cheang, M. C. U., Leung, S., Voduc, D., Vickery, T., Davies, S., Fauron, C., He, X., Hu, Z., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.1370 · Cited by 4,721
Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer
Schmid, P., Adams, S., Rugo, H. S., Schneeweiss, A., Barrios, C. H., Iwata, H., Diéras, V., Hegg, R., Im, S.-A., Shaw Wright, G., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1809615 · Cited by 4,350
The prognostic landscape of genes and infiltrating immune cells across human cancers
Gentles, A. J., Newman, A. M., Liu, C. L., Bratman, S. V., Feng, W., Kim, D., Nair, V. S., Xu, Y., Khuong, A., Hoang, C. D., et al. (2015) · Nature Medicine · doi:10.1038/nm.3909 · Cited by 3,118
Salgado, R., Denkert, C., Demaria, S., Sirtaine, N., Klauschen, F., Pruneri, G., Wienert, S., Van den Eynden, G., Baehner, F. L., Penault-Llorca, F., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdu450 · Cited by 3,113
Nielsen, T. O., Hsu, F. D., Jensen, K., Cheang, M., Karaca, G., Hu, Z., Hernandez-Boussard, T., Livasy, C., Cowan, D., Dressler, L., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0220 · Cited by 2,663
Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs
Albert, M. L., Sauter, B., & Bhardwaj, N. (1998) · Nature · doi:10.1038/32183 · Cited by 2,349
Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer
Prat, A., Parker, J. S., Karginova, O., Fan, C., Livasy, C., Herschkowitz, J. I., He, X., & Perou, C. M. (2010) · Breast Cancer Research · doi:10.1186/bcr2635 · Cited by 2,167
Denkert, C., von Minckwitz, G., Darb-Esfahani, S., Lederer, B., Heppner, B. I., Weber, K. E., Budczies, J., Huober, J., Klauschen, F., Furlanetto, J., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30904-x · Cited by 2,157
Immune checkpoint inhibitors: recent progress and potential biomarkers
Darvin, P., Toor, S. M., Sasidharan Nair, V., & Elkord, E. (2018) · Experimental & Molecular Medicine · doi:10.1038/s12276-018-0191-1 · Cited by 2,035
Giuliano, A. E., Ballman, K. V., McCall, L., Beitsch, P. D., Brennan, M. B., Kelemen, P. R., Ollila, D. W., Hansen, N. M., Whitworth, P. W., Blumencranz, P. W., et al. (2017) · JAMA · doi:10.1001/jama.2017.11470 · Cited by 1,912
The molecular portraits of breast tumors are conserved across microarray platforms
Hu, Z., Fan, C., Oh, D. S., Marron, J., He, X., Qaqish, B. F., Livasy, C., Carey, L. A., Reynolds, E., Dressler, L., et al. (2006) · BMC Genomics · doi:10.1186/1471-2164-7-96 · Cited by 1,491
Lehmann, B. D., Jovanović, B., Chen, X., Estrada, M. V., Johnson, K. N., Shyr, Y., Moses, H. L., Sanders, M. E., & Pietenpol, J. A. (2016) · PLOS ONE · doi:10.1371/journal.pone.0157368 · Cited by 1,426
Burstein, M. D., Tsimelzon, A., Poage, G. M., Covington, K. R., Contreras, A., Fuqua, S. A. W., Savage, M. I., Osborne, C. K., Hilsenbeck, S. G., Chang, J. C., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0432 · Cited by 1,392
Deconstructing the molecular portraits of breast cancer
Prat, A., & Perou, C. M. (2011) · Molecular Oncology · doi:10.1016/j.molonc.2010.11.003 · Cited by 1,343
Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer (kConFab), Savas, P., Virassamy, B., Ye, C., Salim, A., Mintoff, C. P., Caramia, F., Salgado, R., Byrne, D. J., Teo, Z. L., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0078-7 · Cited by 992
Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial
Tutt, A., Tovey, H., Cheang, M. C. U., Kernaghan, S., Kilburn, L., Gazinska, P., Owen, J., Abraham, J., Barrett, S., Barrett-Lee, P., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0009-7 · Cited by 912
Clinical relevance of host immunity in breast cancer: from TILs to the clinic
Savas, P., Salgado, R., Denkert, C., Sotiriou, C., Darcy, P. K., Smyth, M. J., & Loi, S. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.215 · Cited by 890
Triple negative tumours: a critical review
Reis‐Filho, J. S., & Tutt, A. N. J. (2008) · Histopathology · doi:10.1111/j.1365-2559.2007.02889.x · Cited by 884
PD-L1 expression in human cancers and its association with clinical outcomes
Yu, J., Wang, X., Teng, F., & Kong, L. (2016) · OncoTargets and Therapy · doi:10.2147/ott.s105862 · Cited by 787
Gucalp, A., Tolaney, S., Isakoff, S. J., Ingle, J. N., Liu, M. C., Carey, L. A., Blackwell, K., Rugo, H., Nabell, L., Forero, A., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3327 · Cited by 749
Kreike, B., van Kouwenhove, M., Horlings, H., Weigelt, B., Peterse, H., Bartelink, H., & van de Vijver, M. J. (2007) · Breast Cancer Research · doi:10.1186/bcr1771 · Cited by 613
Doane, A. S., Danso, M., Lal, P., Donaton, M., Zhang, L., Hudis, C., & Gerald, W. L. (2006) · Oncogene · doi:10.1038/sj.onc.1209415 · Cited by 603
Muenst, S., Schaerli, A. R., Gao, F., Däster, S., Trella, E., Droeser, R. A., Muraro, M. G., Zajac, P., Zanetti, R., Gillanders, W. E., et al. (2014) · Breast Cancer Research and Treatment · doi:10.1007/s10549-014-2988-5 · Cited by 558
Triple-Negative Breast Cancer: Distinguishing between Basal and Nonbasal Subtypes
Rakha, E. A., Elsheikh, S. E., Aleskandarany, M. A., Habashi, H. O., Green, A. R., Powe, D. G., El-Sayed, M. E., Benhasouna, A., Brunet, J.-S., Akslen, L. A., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2132 · Cited by 489
How basal are triple‐negative breast cancers?
Bertucci, F., Finetti, P., Cervera, N., Esterni, B., Hermitte, F., Viens, P., & Birnbaum, D. (2008) · International Journal of Cancer · doi:10.1002/ijc.23518 · Cited by 443
Dieci, M. V., Radosevic-Robin, N., Fineberg, S., van den Eynden, G., Ternes, N., Penault-Llorca, F., Pruneri, G., D’Alfonso, T. M., Demaria, S., Castaneda, C., et al. (2018) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.10.003 · Cited by 433
Medullary carcinoma of the breast.A clinicopathologic study with 10 year follow-up
Ridolfi, R. L., Rosen, P. P., Port, A., Kinne, D., & Miké, V. (1977) · Cancer · doi:10.1002/1097-0142(197710)40:4<1365::aid-cncr2820400402>3.0.co;2-n · Cited by 424
Androgen Receptor Inhibits Estrogen Receptor-α Activity and Is Prognostic in Breast Cancer
Peters, A. A., Buchanan, G., Ricciardelli, C., Bianco-Miotto, T., Centenera, M. M., Harris, J. M., Jindal, S., Segara, D., Jia, L., Moore, N. L., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-0452 · Cited by 405
Wimberly, H., Brown, J. R., Schalper, K., Haack, H., Silver, M. R., Nixon, C., Bossuyt, V., Pusztai, L., Lannin, D. R., & Rimm, D. L. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0133 · Cited by 397
Børresen-Dale, A.-L. (2003) · Human Mutation · doi:10.1002/humu.10174 · Cited by 354
Lehmann, B. D., Bauer, J. A., Schafer, J. M., Pendleton, C. S., Tang, L., Johnson, K. C., Chen, X., Balko, J. M., Gómez, H., Arteaga, C. L., et al. (2014) · Breast Cancer Research · doi:10.1186/s13058-014-0406-x · Cited by 342
Cimino-Mathews, A., Thompson, E., Taube, J. M., Ye, X., Lu, Y., Meeker, A., Xu, H., Sharma, R., Lecksell, K., Cornish, T. C., et al. (2016) · Human Pathology · doi:10.1016/j.humpath.2015.09.003 · Cited by 336
Ali, H. R., Glont, S.-E., Blows, F. M., Provenzano, E., Dawson, S.-J., Liu, B., Hiller, L., Dunn, J., Poole, C. J., Bowden, S., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv192 · Cited by 304
Chen, M.-S., Wang, S.-F., Hsu, C.-Y., Yin, P.-H., Yeh, T.-S., Lee, H.-C., & Tseng, L.-M. (2017) · Oncotarget · doi:10.18632/oncotarget.23055 · Cited by 296
Androgen receptor in triple negative breast cancer: A potential target for the targetless subtype
Gerratana, L., Basile, D., Buono, G., De Placido, S., Giuliano, M., Minichillo, S., Coinu, A., Martorana, F., De Santo, I., Del Mastro, L., et al. (2018) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2018.06.005 · Cited by 285
Triple-negative/basal-like breast cancer: review
Rakha, E. A., & Ellis, I. O. (2009) · Pathology · doi:10.1080/00313020802563510 · Cited by 281
Barton, V. N., D'Amato, N. C., Gordon, M. A., Lind, H. T., Spoelstra, N. S., Babbs, B. L., Heinz, R. E., Elias, A., Jedlicka, P., Jacobsen, B. M., et al. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0926 · Cited by 239
Recent therapeutic trends and promising targets in triple negative breast cancer
Hwang, S.-Y., Park, S., & Kwon, Y. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.02.006 · Cited by 232
Jung, S.-Y., Kim, H. Y., Nam, B.-H., Min, S. Y., Lee, S. J., Park, C., Kwon, Y., Kim, E.-A., Ko, K. L., Shin, K. H., et al. (2010) · Breast Cancer Research and Treatment · doi:10.1007/s10549-010-0780-8 · Cited by 215
Pareja, F., Geyer, F. C., Marchiò, C., Burke, K. A., Weigelt, B., & Reis-Filho, J. S. (2016) · npj Breast Cancer · doi:10.1038/npjbcancer.2016.36 · Cited by 206
Androgen Receptor Levels and Association with PIK3CA Mutations and Prognosis in Breast Cancer
Gonzalez-Angulo, A. M., Stemke-Hale, K., Palla, S. L., Carey, M., Agarwal, R., Meric-Berstam, F., Traina, T. A., Hudis, C., Hortobagyi, G. N., Gerald, W. L., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1763 · Cited by 205
Expression of PD-L1 and prognosis in breast cancer: a meta-analysis
Zhang, M., Sun, H., Zhao, S., Wang, Y., Pu, H., Wang, Y., & Zhang, Q. (2017) · Oncotarget · doi:10.18632/oncotarget.15532 · Cited by 201
Hennigs, A., Riedel, F., Gondos, A., Sinn, P., Schirmacher, P., Marmé, F., Jäger, D., Kauczor, H.-U., Stieber, A., Lindel, K., et al. (2016) · BMC Cancer · doi:10.1186/s12885-016-2766-3 · Cited by 199
The Spectrum of Triple-Negative Breast Disease
Geyer, F. C., Pareja, F., Weigelt, B., Rakha, E., Ellis, I. O., Schnitt, S. J., & Reis-Filho, J. S. (2017) · The American Journal of Pathology · doi:10.1016/j.ajpath.2017.03.016 · Cited by 179
Tackling the Diversity of Triple-Negative Breast Cancer
Turner, N. C., & Reis-Filho, J. S. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0915 · Cited by 166
Prat, A., Fan, C., Fernández, A., Hoadley, K. A., Martinello, R., Vidal, M., Viladot, M., Pineda, E., Arance, A., Muñoz, M., et al. (2015) · BMC Medicine · doi:10.1186/s12916-015-0540-z · Cited by 164
Genomic landscape of adenoid cystic carcinoma of the breast
Martelotto, L. G., Filippo, M. R. D., Ng, C. K. Y., Natrajan, R., Fuhrmann, L., Cyrta, J., Piscuoglio, S., Wen, H., Lim, R. S., Shen, R., et al. (2015) · The Journal of Pathology · doi:10.1002/path.4573 · Cited by 161
Minireview: Basal-Like Breast Cancer: From Molecular Profiles to Targeted Therapies
Toft, D. J., & Cryns, V. L. (2011) · Molecular Endocrinology · doi:10.1210/me.2010-0164 · Cited by 161
Recent treatment progress of triple negative breast cancer
Chang-Qing, Y., Jie, L., Shi-Qi, Z., Kun, Z., Zi-Qian, G., Ran, X., Hui-Meng, L., Ren-Bin, Z., Gang, Z., Da-Chuan, Y., et al. (2020) · Progress in Biophysics and Molecular Biology · doi:10.1016/j.pbiomolbio.2019.11.007 · Cited by 159
Pandy, J. G. P., Balolong-Garcia, J. C., Cruz-Ordinario, M. V. B., & Que, F. V. (2019) · BMC Cancer · doi:10.1186/s12885-019-6253-5 · Cited by 157
Thike, A. A., Chong, L. Y.-Z., Cheok, P. Y., Li, H. H., Yip, G. W. C., Bay, B., Tse, G. M.-K., Iqbal, J., & Tan, P. H. (2013) · Modern Pathology · doi:10.1038/modpathol.2013.145 · Cited by 155
Choi, J. E., Kang, S. H., Lee, S. J., & Bae, Y. K. (2014) · Annals of Surgical Oncology · doi:10.1245/s10434-014-3984-z · Cited by 153
Marchiò, C., Weigelt, B., & Reis-Filho, J. S. (2010) · Journal of Clinical Pathology · doi:10.1136/jcp.2009.073908 · Cited by 146
Diaz, L. K., Cryns, V. L., Symmans, W. F., & Sneige, N. (2007) · Advances in Anatomic Pathology · doi:10.1097/pap.0b013e3181594733 · Cited by 132
Prognostic value of androgen receptor in triple negative breast cancer: A meta-analysis
Wang, C., Pan, B., Zhu, H., Zhou, Y., Mao, F., Lin, Y., Xu, Q., & Sun, Q. (2016) · Oncotarget · doi:10.18632/oncotarget.10208 · Cited by 132
Kensler, K. H., Regan, M. M., Heng, Y. J., Baker, G. M., Pyle, M. E., Schnitt, S. J., Hazra, A., Kammler, R., Thurlimann, B. J. K., Colleoni, M. A., et al. (2019) · Breast Cancer Research · doi:10.1186/s13058-019-1118-z · Cited by 131
Triple negative breast cancer – prognostic role of immune-related factors: a systematic review
Stovgaard, E. S., Nielsen, D. L., Høgdall, E. V. S., & Balslev, E. (2017) · Acta Oncologica · doi:10.1080/0284186x.2017.1400180 · Cited by 130
Sobral‐Leite, M., de Vijver, K. K. V., Michaut, M., van der Linden, R., Hooijer, G. K. J., Horlings, H. M., Severson, T., Mulligan, A. M., Weerasooriya, N., Sanders, J., et al. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1509820 · Cited by 127
Božović‐Spasojević, I., Zardavas, D., Brohée, S., Ameye, L., Fumagalli, D., Ades, F., de Azambuja, E., Barèche, Y., Piccart, M. J., Paesmans, M., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0979 · Cited by 120
Distant metastasis in triple-negative breast cancer
Tseng, L., Hsu, N., Chen, S.-C., Lu, Y., Lin, C., CHANG, D. Y., LI, H., LIN, Y. C., CHANG, H. K., Chao, T., et al. (2013) · Neoplasma · doi:10.4149/neo_2013_038 · Cited by 118
Predicting response and survival in chemotherapy-treated triple-negative breast cancer
Prat, A., Lluch, A. M., Albanell, J., Barry, W. T., Fan, C., Chacón, J. I., Parker, J. S., Calvo, L., Plazaola, A., Arcusa, À., et al. (2014) · British Journal of Cancer · doi:10.1038/bjc.2014.444 · Cited by 117
Giovannelli, P., Donato, M. D., Auricchio, F., Castoria, G., & Migliaccio, A. (2019) · Scientific Reports · doi:10.1038/s41598-019-41016-4 · Cited by 111
Krings, G., & Chen, Y. (2018) · Modern Pathology · doi:10.1038/s41379-018-0081-z · Cited by 104
Botti, G., Collina, F., Scognamiglio, G., Rao, F., Peluso, V., Cecio, R. D., Piezzo, M., Landi, G., Laurentiis, M. D., Cantile, M., et al. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18020459 · Cited by 99
Li, X., Wetherilt, C. S., Krishnamurti, U., Yang, J. L., Ma, Y., Styblo, T. M., Meisel, J. L., Peng, L., Siddiqui, M. T., Cohen, C., et al. (2016) · American Journal of Clinical Pathology · doi:10.1093/ajcp/aqw134 · Cited by 94
Basal-like Breast Carcinoma: From Expression Profiling to Routine Practice
Rakha, E. A., & Reis-Filho, J. S. (2009) · Archives of Pathology & Laboratory Medicine · doi:10.5858/133.6.860 · Cited by 91
Fusco, N., Geyer, F. C., Filippo, M. R. D., Martelotto, L. G., Ng, C. K. Y., Piscuoglio, S., Guerini‐Rocco, E., Schultheis, A. M., Fuhrmann, L., Wang, L., et al. (2016) · Modern Pathology · doi:10.1038/modpathol.2016.134 · Cited by 87
Asano, Y., Kashiwagi, S., Onoda, N., Kurata, K., Morisaki, T., Noda, S., Takashima, T., Ohsawa, M., Kitagawa, S., & Hirakawa, K. (2016) · British Journal of Cancer · doi:10.1038/bjc.2015.434 · Cited by 84
Regulation of Immunity in Breast Cancer
Edechi, C. A., Ikeogu, N. M., Uzonna, J. E., & Myal, Y. (2019) · Cancers · doi:10.3390/cancers11081080 · Cited by 78
Lozada, J. R., Basili, T., Pareja, F. G., Alemar, B., Paula, A. D. C., Gularte‐Mérida, R., Giri, D. D., Querzoli, P., Cserni, G., Rakha, E. A., et al. (2018) · Histopathology · doi:10.1111/his.13522 · Cited by 71
Dieci, M. V., Tsvetkova, V., Griguolo, G., Miglietta, F., Mantiero, M., Tasca, G., Cumerlato, E., Giorgi, C. A., Giarratano, T., Faggioni, G., et al. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00452 · Cited by 71
Xu, M., Yuan, Y., Yan, P., Jiang, J., Ma, P., Niu, X., Ma, S., Cai, H., & Yang, K. (2020) · Clinical Breast Cancer · doi:10.1016/j.clbc.2020.01.002 · Cited by 70
Basal-Like Breast Cancer: Update on Clinicopathologic, Immunohistochemical, and Molecular Features
Leidy, J., Khan, A. A., & Kandil, D. H. (2013) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2012-0439-ra · Cited by 63
Tramm, T., Caterino, T. D., Jylling, A.-M. B., Lelkaitis, G., Lænkholm, A., Ragó, P., Tabor, T. P., Talman, M., & Vouza, E. (2017) · Acta Oncologica · doi:10.1080/0284186x.2017.1403040 · Cited by 59
Premenopausal serum androgens and breast cancer risk: a nested case-control study
Zeleniuch‐Jacquotte, A., Afanasyeva, Y., Kaaks, R., Rinaldi, S., Scarmo, S., Liu, M., Arslan, A. A., Toniolo, P. G., Shore, R. E., & Koenig, K. L. (2012) · Breast Cancer Research · doi:10.1186/bcr3117 · Cited by 57
Triple-Negative Breast Cancer: Clinical and Histological Correlations
Elsawaf, Z. M., & Sinn, H. (2011) · Breast Care · doi:10.1159/000331643 · Cited by 55
The Spatiotemporal Evolution of Lymph Node Spread in Early Breast Cancer
Barry, P. A., Vatsiou, A. I., Spiteri, I., Nichol, D., Cresswell, G. D., Acar, A., Trahearn, N., Hrebien, S., García-Murillas, I., Chkhaidze, K., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-3374 · Cited by 43
Wang, D., Gendoo, D. M. A., Ben‐David, Y., Woodgett, J. R., & Zacksenhaus, E. (2019) · Breast Cancer Research · doi:10.1186/s13058-019-1098-z · Cited by 42
Molinero, L. L., Li, Y., Chang, C., Maund, S. L., Berg, M., Harrison, J., Fassò, M., O'Hear, C. E., Hegde, P. S., & Emens, L. A. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0740-8 · Cited by 35
Lavasani, M. A., & Moinfar, F. (2012) · Journal of Biophotonics · doi:10.1002/jbio.201100097 · Cited by 33
Walsh, E. M., Shalaby, A., O’Loughlin, M., Keane, N., Webber, M., Kerin, M. J., Keane, M., Glynn, S. A., & Callagy, G. M. (2018) · Breast Cancer Research and Treatment · doi:10.1007/s10549-018-5066-6 · Cited by 26
Patterns of Mutation Enrichment in Metastatic Triple-Negative Breast Cancer
Saravia, C. H., Flores, C. J., Schwarz, L. J., Bravo, L., Zavaleta, J., Araujo, J. M., Neciosup, S. P., & Pinto, J. A. (2019) · Clinical Medicine Insights Oncology · doi:10.1177/1179554919868482 · Cited by 26
Tan, W., Xie, X., Huang, Z., Chen, L., Tang, W., Zhu, R., Ye, X., Zhang, X., Pan, L., Gao, J. H., et al. (2019) · Artificial Cells Nanomedicine and Biotechnology · doi:10.1080/21691401.2019.1703731 · Cited by 25
Kim, S., Park, H. S., Kim, J. Y., Ryu, J., Park, S., & Kim, S. I. (2016) · Yonsei Medical Journal · doi:10.3349/ymj.2016.57.5.1192 · Cited by 21
First international TNBC conference meeting report
Rida, P. C. G., Ogden, A., Ellis, I. O., Varga, Z., Wolff, A. C., Traina, T. A., Hatzis, C., Palmer, J. R., Ambrosone, C. B., Lehmann, B. D., et al. (2018) · Breast Cancer Research and Treatment · doi:10.1007/s10549-018-4692-3 · Cited by 18
Kaya, V., Yıldırım, M., Yazıcı, G., Gunduz, S. G., Bozcuk, H. S., & Paydaş, S. (2018) · Europe PMC (PubMed Central) · doi:10.22034/apjcp.2018.19.5.1169 · Cited by 17
The Prognostic Value of Nodal Staging in Triple-Negative Breast Cancer — A Cohort from China
Liu, Y., Hao, S., Chen, S., Liang, H., Sun, X., Yang, W.-T., & Shao, Z. (2018) · Scientific Reports · doi:10.1038/s41598-018-23999-8 · Cited by 17
Characteristics, behaviour and role of biomarkers in metastatic triple-negative breast cancer
Goto, Y., Thike, A. A., Ong, C. C. H., Lim, J. X., Nasir, N. D. M., Li, H., Koh, V. C. Y., Chen, X.-Y., Yeong, J. P.-S., Sasano, H., et al. (2019) · Journal of Clinical Pathology · doi:10.1136/jclinpath-2019-206078 · Cited by 12
Cited by
Recent advances in targeted strategies for triple-negative breast cancer
Zhu, S., Wu, Y., Song, B., Yi, M., Yan, Y., Mei, Q., & Wu, K. (2023) · Journal of Hematology & Oncology · doi:10.1186/s13045-023-01497-3 · Cited by 331
Wu, S., Wu, X., Wang, Q., Chen, Z., Li, L., Chen, H., & Qi, H. (2024) · Phytomedicine · doi:10.1016/j.phymed.2024.156130 · Cited by 27
Metadata
- Authors
- Borri, F., & Granaglia, A.
- Venue
- Seminars in Cancer Biology
- Publisher
- Elsevier BV
- Published
- 2021-07
- Volume
- 72
- Pages
- 136-145
- ISSN
- 1044-579X (ISSN-L)
- OpenAlex
- W3035007653
- Cited by
- 300
- References
- 91
- FWCI
- 8.63
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.